Pharma’s 2025 Reality Check: R&D Resets, Cash Discipline, and Commercial Bets
The pharmaceutical and biotech landscape in 2026 is defined less by headline‑grabbing breakthroughs and more by how companies are adjusting their R&D footprints, capital structures, and commercial expectations. A Pharmavanguard…